94 related articles for article (PubMed ID: 32783759)
1. What Kind of Evidence Is Needed to Dictate Practice Regarding Inhibitors of the Renin-Angiotensin System in COVID-19?
Elijovich F; Laffer CL
Hypertension; 2020 Sep; 76(3):665-669. PubMed ID: 32783759
[No Abstract] [Full Text] [Related]
2. Renin-Angiotensin System Blockade in COVID-19: Good, Bad, or Indifferent?
Bloch MJ
J Am Coll Cardiol; 2020 Jul; 76(3):277-279. PubMed ID: 32674791
[TBL] [Abstract][Full Text] [Related]
3. Inquiring Into Benefits of Independent Activation of Nonclassical Renin-angiotensin System in the Clinical Prognosis and Reduction of COVID-19 Mortality.
Álvarez-Aragón LM; Cuesta-Muñoz AL; Álvarez-López I
Clin Infect Dis; 2020 Jul; 71(15):894-895. PubMed ID: 32266375
[No Abstract] [Full Text] [Related]
4. Renin-Angiotensin-Aldosterone System Inhibitors Impact on COVID-19 Mortality: What's Next for ACE2?
Patel AB; Verma A
Clin Infect Dis; 2020 Nov; 71(16):2129-2131. PubMed ID: 32442259
[No Abstract] [Full Text] [Related]
5. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.
Guo X; Zhu Y; Hong Y
Hypertension; 2020 Aug; 76(2):e13-e14. PubMed ID: 32458694
[No Abstract] [Full Text] [Related]
6. [Hypertension, RAAS blockade and risk in COVID-19 patients].
Spaak J; Kahan T
Lakartidningen; 2020 Jun; 117():. PubMed ID: 32594472
[TBL] [Abstract][Full Text] [Related]
7. Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs.
Ruilope LM; Tamargo J; Ruiz-Hurtado G
Eur Heart J; 2020 Jun; 41(22):2067-2069. PubMed ID: 32498078
[No Abstract] [Full Text] [Related]
8. Is there enough evidence to discontinue the renin-angiotensin system inhibitors in patients with COVID-19?
Bobkova I; Kamyshova E; Rudenko T; Stavrovskaya E; Moiseev S
Med Hypotheses; 2020 Oct; 143():109888. PubMed ID: 32480248
[No Abstract] [Full Text] [Related]
9. Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections.
Speth RC
Drug Dev Res; 2020 Sep; 81(6):643-646. PubMed ID: 32304146
[No Abstract] [Full Text] [Related]
10. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.
Conversano A; Melillo F; Napolano A; Fominskiy E; Spessot M; Ciceri F; Agricola E
Hypertension; 2020 Aug; 76(2):e10-e12. PubMed ID: 32383626
[No Abstract] [Full Text] [Related]
11. Controversial Relationship Between Renin-Angiotensin System Inhibitors and Severity of COVID-19: Announcing a Large Multicentre Case-Control Study in Italy.
Di Castelnuovo A; De Caterina R; de Gaetano G; Iacoviello L
Hypertension; 2020 Aug; 76(2):312-313. PubMed ID: 32383624
[No Abstract] [Full Text] [Related]
12. The Renin-Angiotensin system and SARS-CoV-2 infection: A role for the ACE2 receptor?
Sever P; Johnston SL
J Renin Angiotensin Aldosterone Syst; 2020; 21(2):1470320320926911. PubMed ID: 32403977
[No Abstract] [Full Text] [Related]
13. COVID-19, Renin-Angiotensin System, and Hematopoiesis.
Çiftçiler R; Haznedaroğlu İC
Turk J Haematol; 2020 Aug; 37(3):207-208. PubMed ID: 32394689
[No Abstract] [Full Text] [Related]
14. Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19.
Williams B; Zhang Y
Lancet; 2020 May; 395(10238):1671-1673. PubMed ID: 32416786
[No Abstract] [Full Text] [Related]
15. Good things come in threes (and sometimes fours): Update on renin-angiotensin-aldosterone system inhibitors and COVID-19.
Quinn KL; Fralick M; Zipursky JS; Stall NM
CMAJ; 2020 Jun; 192(22):E611. PubMed ID: 32575050
[No Abstract] [Full Text] [Related]
16. Reply to Siniorakis et al., "COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure".
Fedson DS; Opal SM; Rordam OM
mBio; 2020 May; 11(3):. PubMed ID: 32471831
[No Abstract] [Full Text] [Related]
17. Clinical Features of COVID-19 in Patients With Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients.
Pan W; Zhang J; Wang M; Ye J; Xu Y; Shen B; He H; Wang Z; Ye D; Zhao M; Luo Z; Liu M; Zhang P; Gu J; Liu M; Li D; Liu J; Wan J
Hypertension; 2020 Sep; 76(3):732-741. PubMed ID: 32654555
[TBL] [Abstract][Full Text] [Related]
18. RAAS Inhibitors and Risk of Covid-19.
Sriram K; Loomba R; Insel PA
N Engl J Med; 2020 Nov; 383(20):1991-1992. PubMed ID: 33108103
[No Abstract] [Full Text] [Related]
19. RAAS Inhibitors and Risk of Covid-19.
Angeli F; Verdecchia P; Reboldi G
N Engl J Med; 2020 Nov; 383(20):1990-1991. PubMed ID: 33108102
[No Abstract] [Full Text] [Related]
20. Covid-19: the renin-angiotensin system imbalance hypothesis.
Lanza K; Perez LG; Costa LB; Cordeiro TM; Palmeira VA; Ribeiro VT; Simões E Silva AC
Clin Sci (Lond); 2020 Jun; 134(11):1259-1264. PubMed ID: 32507883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
